PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32004509-0 2020 Metformin rescues Parkin protein expression and mitophagy in high glucose-challenged human renal epithelial cells by inhibiting NF-kappaB via PP2A activation. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 128-137 33014814-0 2020 Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-kappaB Signaling Pathway. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 93-102 33014814-5 2020 The most commonly used antidiabetic drug metformin has demonstrated antitumor effects associated with NF-kappaB inhibition. Metformin 41-50 nuclear factor kappa B subunit 1 Homo sapiens 102-111 33014814-11 2020 Mechanistically, those effects of metformin were associated with activation of AMPK, resulting in the inhibition of downstream ERK/NF-kappaB signaling. Metformin 34-43 nuclear factor kappa B subunit 1 Homo sapiens 131-140 32004509-10 2020 Metformin increased PRKN gene transcription while reducednuclear factor kappa B (NF-kappaB) activation but not that of p53 or ATF4. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 81-90 33184242-13 2020 Metformin pre-treatment reduced NF-kappaB activation in human and rat cardiomyocytes apoptosis that was elicited by high-glucose stimulation, and this effect of metformin could be blocked by okadaic acid treatment. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 32-41 33184242-13 2020 Metformin pre-treatment reduced NF-kappaB activation in human and rat cardiomyocytes apoptosis that was elicited by high-glucose stimulation, and this effect of metformin could be blocked by okadaic acid treatment. Metformin 161-170 nuclear factor kappa B subunit 1 Homo sapiens 32-41 30754072-0 2019 NF-kappaB as the mediator of metformin"s effect on ageing and ageing-related diseases. Metformin 29-38 nuclear factor kappa B subunit 1 Homo sapiens 0-9 32258978-2 2020 We have recently reported that the antidiabetic drug metformin exerts antitumor effects on ESCC by inhibition of nuclear factor kappa B (NF-kappaB) nuclear translocation. Metformin 53-62 nuclear factor kappa B subunit 1 Homo sapiens 113-135 32258978-2 2020 We have recently reported that the antidiabetic drug metformin exerts antitumor effects on ESCC by inhibition of nuclear factor kappa B (NF-kappaB) nuclear translocation. Metformin 53-62 nuclear factor kappa B subunit 1 Homo sapiens 137-146 31337349-0 2019 Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-kappaB pathways. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 86-95 31337349-14 2019 CONCLUSION: These results suggest that MTF inhibits IL-6-induced EMT, cell proliferation, and migration of primary breast cancer cells by preventing the activation of STAT3 and NF-kappaB. Metformin 39-42 nuclear factor kappa B subunit 1 Homo sapiens 177-186 30845774-5 2019 Of note, abdominal fat tissue of obese pre-DM patients treated with metformin therapy presented higher SIRT6 expression and lower NF-kappaB, PPAR-gamma, and SREBP-1 expression levels compared to pre-DM control group. Metformin 68-77 nuclear factor kappa B subunit 1 Homo sapiens 130-139 30628691-0 2019 Protective effects of metformin on lipopolysaccharide-induced airway epithelial cell injury via NF-kappaB signaling inhibition. Metformin 22-31 nuclear factor kappa B subunit 1 Homo sapiens 96-105 30628691-12 2019 The results demonstrated that metformin inhibited NF-kappaB mRNA expression and the nuclear translocation of NF-kappaB p65. Metformin 30-39 nuclear factor kappa B subunit 1 Homo sapiens 50-59 30628691-12 2019 The results demonstrated that metformin inhibited NF-kappaB mRNA expression and the nuclear translocation of NF-kappaB p65. Metformin 30-39 nuclear factor kappa B subunit 1 Homo sapiens 109-118 30628691-13 2019 To the best of our knowledge, the present study was the first to demonstrate that metformin ameliorated LPS-induced bronchial epithelial cell injury via NF-kappaB signaling suppression. Metformin 82-91 nuclear factor kappa B subunit 1 Homo sapiens 153-162 30765814-4 2019 Metformin was demonstrated to block LCA-stimulated ROS production, in turn suppressing NF-kappaB signaling that was critical for IL-8 upregulation. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 87-96 30765814-7 2019 In conclusion, metformin inhibited NADPH oxidase, which in turn suppressed ROS production and NF-kappaB activation to prevent IL-8 upregulation stimulated by LCA; this prevention thus obstructed endothelial cell proliferation and tubelike formation. Metformin 15-24 nuclear factor kappa B subunit 1 Homo sapiens 94-103 30520054-5 2019 Immunofluorescence staining and western blot analysis showed that metformin inhibited the nuclear localization of p65, a subunit of nuclear factor NF-kappaB. Metformin 66-75 nuclear factor kappa B subunit 1 Homo sapiens 147-156 30520054-6 2019 In addition, metformin suppressed the transcription activity of NF-kappaB by inhibiting the degradation of IkappaBalpha. Metformin 13-22 nuclear factor kappa B subunit 1 Homo sapiens 64-73 30520054-3 2019 In the present study, we examined the role of metformin in nuclear factor kappa B (NF-kappaB)-mediated inflammatory responses in HaCaT cells, a cell line for the keratinocyte. Metformin 46-55 nuclear factor kappa B subunit 1 Homo sapiens 59-81 30520054-7 2019 The inhibitory effect of metformin on NF-kappaB signalling is comparable with a specific IKKbeta inhibitor BI605906. Metformin 25-34 nuclear factor kappa B subunit 1 Homo sapiens 38-47 30520054-3 2019 In the present study, we examined the role of metformin in nuclear factor kappa B (NF-kappaB)-mediated inflammatory responses in HaCaT cells, a cell line for the keratinocyte. Metformin 46-55 nuclear factor kappa B subunit 1 Homo sapiens 83-92 29396886-0 2018 Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. Metformin 21-30 nuclear factor kappa B subunit 1 Homo sapiens 58-80 30307719-12 2018 Metformin combined with CO-1686 synergistically inhibited the p-IKBalpha, p-IKKalpha/beta, p50, and p65. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 91-94 30097812-3 2018 By preventing the activation of NF-kappaB, metformin exhibits anti-inflammatory properties. Metformin 43-52 nuclear factor kappa B subunit 1 Homo sapiens 32-41 29630425-8 2018 RESULTS: Metformin suppressed LPS-induced IP-10 and MCP-1 production as well as LPS-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase (ERK), and nuclear factor-kappa B (NF-kappaB). Metformin 9-18 nuclear factor kappa B subunit 1 Homo sapiens 196-218 29630425-8 2018 RESULTS: Metformin suppressed LPS-induced IP-10 and MCP-1 production as well as LPS-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase (ERK), and nuclear factor-kappa B (NF-kappaB). Metformin 9-18 nuclear factor kappa B subunit 1 Homo sapiens 220-229 29630425-11 2018 Suppressive effects of metformin on IP-10 production might be attributed at least partially to the JNK, p38, ERK, and NF-kappaB pathways as well as to epigenetic regulation through the acetylation of histones H3 and H4. Metformin 23-32 nuclear factor kappa B subunit 1 Homo sapiens 118-127 30009823-10 2018 In addition, activation of AMPK by metformin suppressed NF-kappaB-mediated autophagy activation and down-regulation of RND3 and therefore reduced RVSP, RVHI, and %MT in MCT-induced PAH. Metformin 35-44 nuclear factor kappa B subunit 1 Homo sapiens 56-65 29772687-6 2018 The results demonstrate that metformin exerts growth inhibitory effects on cultured HT29 cells by increasing both apoptosis and autophagy; moreover, it affects the survival of cultured cells inhibiting the transcriptional activation of Nuclear factor E2-related factor 2 (NRF-2) and nuclear factor-kappa B (NF-kappaB). Metformin 29-38 nuclear factor kappa B subunit 1 Homo sapiens 283-305 29772687-6 2018 The results demonstrate that metformin exerts growth inhibitory effects on cultured HT29 cells by increasing both apoptosis and autophagy; moreover, it affects the survival of cultured cells inhibiting the transcriptional activation of Nuclear factor E2-related factor 2 (NRF-2) and nuclear factor-kappa B (NF-kappaB). Metformin 29-38 nuclear factor kappa B subunit 1 Homo sapiens 307-316 29396886-7 2018 We found that localization of NF-kappaB in the nucleus was reduced after metformin treatment. Metformin 73-82 nuclear factor kappa B subunit 1 Homo sapiens 30-39 29396886-8 2018 This suggests that metformin inhibited the activation of NF-kappaB. Metformin 19-28 nuclear factor kappa B subunit 1 Homo sapiens 57-66 29396886-12 2018 In conclusion, metformin showed multiple antitumor effects such as growth suppression, invasion inhibition, and control of EMT by inhibiting NF-kappaB localization on ESCC. Metformin 15-24 nuclear factor kappa B subunit 1 Homo sapiens 141-150 29147073-6 2017 Our data indicated that metformin suppressed LPS-induced CXCL8 expression in a dose-dependent manner through inhibiting NF-kappaB, but not AP-1 and C/EBP, activities under the conditions we used. Metformin 24-33 nuclear factor kappa B subunit 1 Homo sapiens 120-129 28159472-11 2017 NF-kappaB is a transcription factor with a key role in the expression of a variety of genes involved in inflammatory responses, and metformin did prevent the AGE-mediated increase in NF-kappaB mRNA and protein levels in the hNSCs exposed to AGE. Metformin 132-141 nuclear factor kappa B subunit 1 Homo sapiens 183-192 29147073-7 2017 This inhibitory effect of metformin is achieved through dampening LPS-induced NF-kappaB nuclear translocation. Metformin 26-35 nuclear factor kappa B subunit 1 Homo sapiens 78-87 27424158-0 2016 Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFkappaB signaling. Metformin 14-23 nuclear factor kappa B subunit 1 Homo sapiens 127-135 27246734-7 2016 Metformin significantly reduced the expression of NF-kappaB. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 50-59 27424158-12 2016 In conclusion, here, we report that metformin and exenatide inhibit the proinflammatory phenotype of human monocytes/macrophages via influence on MAPK, C/EBP beta, and NFkappaB. Metformin 36-45 nuclear factor kappa B subunit 1 Homo sapiens 168-176 27706018-2 2016 We found that AICAR or metformin acts as a regulator of LPS/NF-kappaB-or hypoxia/NF-kappaB-mediated cyclooxygenase induction by an AMPK-dependent mechanism with interactions between p65-NF-kappaB phosphorylation and acetylation, including in a human bladder cancer cell line (T24). Metformin 23-32 nuclear factor kappa B subunit 1 Homo sapiens 60-80 26141671-6 2015 In addition, treatment with metformin significantly reduced the expression of IL-6 and TNF-alpha at the messenger RNA level and attenuated nuclear factor kappa B (NF-kappaB) DNA binding activity in MNCs. Metformin 28-37 nuclear factor kappa B subunit 1 Homo sapiens 139-161 26391700-11 2015 Treatment with cyproterone acetate/ethinyloestradiol with addition of metformin reduced the level of NF-kappaB, TGF-beta1 and HOMA-IR and increased the level of TSP-1. Metformin 70-79 nuclear factor kappa B subunit 1 Homo sapiens 101-110 26141671-9 2015 Moreover, we found that metformin treatment dramatically induced SIRT1 expression, blocked p65 acetylation, and inhibited NF-kappaB activity and the expression of inflammatory factors in MNCs in vitro. Metformin 24-33 nuclear factor kappa B subunit 1 Homo sapiens 122-131 26141671-10 2015 We conclude that metformin has a novel direct protective role to ameliorate the proinflammatory response through SIRT1 induction, p65 acetylation reduction, NF-kappaB inactivation, and inflammatory inhibition in peripheral blood MNCs of patients with carotid artery AS. Metformin 17-26 nuclear factor kappa B subunit 1 Homo sapiens 157-166 26141671-6 2015 In addition, treatment with metformin significantly reduced the expression of IL-6 and TNF-alpha at the messenger RNA level and attenuated nuclear factor kappa B (NF-kappaB) DNA binding activity in MNCs. Metformin 28-37 nuclear factor kappa B subunit 1 Homo sapiens 163-172 20852028-12 2010 In vitro migration and angiogenesis were significantly increased in serum from PCOS women (P < 0.01) compared with matched control subjects; these effects were significantly attenuated by metformin treatment (P < 0.01) plausibly through the regulation of omentin-1 levels via NF-kappaB and Akt pathways. Metformin 191-200 nuclear factor kappa B subunit 1 Homo sapiens 282-291 25772174-5 2015 Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor kappaB (NFkappaB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. Metformin 28-37 nuclear factor kappa B subunit 1 Homo sapiens 88-109 25772174-5 2015 Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor kappaB (NFkappaB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. Metformin 28-37 nuclear factor kappa B subunit 1 Homo sapiens 111-119 24243637-9 2014 Treatment of adipocyte fractions or SGBS adipocytes with metformin or acetylsalicylic acid, which target C/EBPbeta and NF-kappaB/RelA signaling, attenuated the IL-1alpha induction of 11beta-HSD1 (P<=.002). Metformin 57-66 nuclear factor kappa B subunit 1 Homo sapiens 119-128 23521863-0 2013 Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 89-98 23521863-3 2013 Bioinformatic analysis of genes downregulated by metformin suggests that the drug blocks the activity of the transcription factor NF-kappaB. Metformin 49-58 nuclear factor kappa B subunit 1 Homo sapiens 130-139 23521863-4 2013 In agreement, metformin prevented the translocation of NF-kappaB to the nucleus and inhibited the phosphorylation of IkappaB and IKKalpha/beta, events required for activation of the NF-kappaB pathway. Metformin 14-23 nuclear factor kappa B subunit 1 Homo sapiens 55-64 23521863-4 2013 In agreement, metformin prevented the translocation of NF-kappaB to the nucleus and inhibited the phosphorylation of IkappaB and IKKalpha/beta, events required for activation of the NF-kappaB pathway. Metformin 14-23 nuclear factor kappa B subunit 1 Homo sapiens 182-191 23521863-5 2013 These effects were not dependent on AMPK activation or on the context of cellular senescence, as metformin inhibited the NF-kappaB pathway stimulated by lipopolysaccharide (LPS) in ampk null fibroblasts and in macrophages. Metformin 97-106 nuclear factor kappa B subunit 1 Homo sapiens 121-130 23510106-3 2013 In a paper published in Proceedings of the National Academy of Sciences of the United States of America, Hirsch and colleagues show that metformin interferes with a signaling pathway, mediated by the transcription factor NF-kappaB, which drives cell transformation and is required for the maintenance of cancer stem cells. Metformin 137-146 nuclear factor kappa B subunit 1 Homo sapiens 221-230 23277563-2 2013 In a Src-inducible model of cellular transformation, metformin inhibits the earliest known step in the process, activation of the inflammatory transcription factor NF-kappaB. Metformin 53-62 nuclear factor kappa B subunit 1 Homo sapiens 164-173 23277563-5 2013 The antitransformation effect of metformin can be bypassed by overexpression of Lin28B or IL1beta, downstream targets of NF-kappaB. Metformin 33-42 nuclear factor kappa B subunit 1 Homo sapiens 121-130 23277563-6 2013 Metformin preferentially inhibits nuclear translocation of NF-kappaB and phosphorylation of STAT3 in cancer stem cells compared with non-stem cancer cells in the same population. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 59-68 25674239-19 2014 Agents that may be considered based on existing data include: bortezomib to inhibit NF-kappaB pathway activation; metformin to inhibit both NF-kappaB and mTORC2 and histone deacteylase inhibitors to inhibit mTORC2 pathway signaling. Metformin 114-123 nuclear factor kappa B subunit 1 Homo sapiens 140-149 34911941-6 2021 Time-lapse microscopy and medium transfer experiments disclosed the non-cell autonomous, paracrine nature of these mechanisms, and pharmacological interference with senescence-associated cytokine production by the NF-kappaB inhibitor metformin significantly improved radiotherapeutic performance in vitro and in vivo. Metformin 234-243 nuclear factor kappa B subunit 1 Homo sapiens 214-223 15983226-9 2005 Treatment of HASMCs with metformin decreased leptin-induced ROS production and activation of PKC, ERK1/2, and NF-kappaB. Metformin 25-34 nuclear factor kappa B subunit 1 Homo sapiens 110-119 34844106-8 2022 On the one hand these effects are likely attributed to the ability of metformin to inactivate NF-kappaB in an AMPK-dependent mechanism and on the other hand to the ability of the empagliflozin to inhibit the MAPKs, p38 and ERK1/2. Metformin 70-79 nuclear factor kappa B subunit 1 Homo sapiens 94-103 16385087-5 2006 Investigation of potential signaling pathways demonstrated that metformin diminished IL-1beta-induced activation and nuclear translocation of nuclear factor-kappa B (NF-kappaB) in SMCs. Metformin 64-73 nuclear factor kappa B subunit 1 Homo sapiens 142-164 16385087-5 2006 Investigation of potential signaling pathways demonstrated that metformin diminished IL-1beta-induced activation and nuclear translocation of nuclear factor-kappa B (NF-kappaB) in SMCs. Metformin 64-73 nuclear factor kappa B subunit 1 Homo sapiens 166-175 16385087-9 2006 CONCLUSIONS: These data suggest that metformin can exert a direct vascular anti-inflammatory effect by inhibiting NF-kappaB through blockade of the PI3K-Akt pathway. Metformin 37-46 nuclear factor kappa B subunit 1 Homo sapiens 114-123 34895136-3 2021 Many studies showed that metformin exerted beneficial effects on multiple cardiovascular diseases by mediating multiple proteins such as AMPK, NF-kappaB, and AKT. Metformin 25-34 nuclear factor kappa B subunit 1 Homo sapiens 143-152 35496297-11 2022 Metformin and TQ inhibited the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling and induced apoptosis in tested cell lines and primary cells. Metformin 0-9 nuclear factor kappa B subunit 1 Homo sapiens 95-104 34895136-13 2021 AMPK activation and NF-kappaB inhibition could inhibit AVICs calcification induced by PM treatment; however, AMPK and AKT inhibition reversed the protective effect of metformin. Metformin 167-176 nuclear factor kappa B subunit 1 Homo sapiens 20-29 34163481-3 2021 The mechanisms by which metformin regulates the function of macrophages include AMPK, AMPK independent targets, NF-kappaB, ABCG5/8, Sirt1, FOXO1/FABP4 and HMGB1. Metformin 24-33 nuclear factor kappa B subunit 1 Homo sapiens 112-121 35496297-14 2022 A combination of 1.25 mM metformin and 0.625 microM TQ increased the levels of cleaved poly (ADP-ribose) polymerase (PARP), decreased the levels of proliferation regulatory proteins, and inhibited protein kinase B (Akt) and NF-kappaB signaling in primary CLL cells. Metformin 25-34 nuclear factor kappa B subunit 1 Homo sapiens 224-233 33524789-7 2021 Secondly, some signaling pathways were involved in the process of metformin inhibiting autophagy, such as AMPK-related signaling pathways (AMPK/NF-kappaB and other undetermined AMPK-related signaling pathways), Hedgehog, miR-570-3p, miR-142-3p, and MiR-3127-5p. Metformin 66-75 nuclear factor kappa B subunit 1 Homo sapiens 144-153